Tobramycin versus gentamicin, in combination with cephalotin and carbenecillin, in patients undergoing bone marrow transplantation

A. Bacigalupo, M. T. van Lint, C. Volta, G. Grazi, O. Soro, M. Podestà, F. Frassoni, A. Marmont

Research output: Contribution to journalArticlepeer-review

Abstract

36 patients with severe aplastic anemia or acute leukemia undergoing bone marrow transplantation or intensive hematologic treatments were randomized to receive gentamicin (1 mg/kg/iv q8h) or tobramycin (1 mg/kg/iv q8h) in combination with carbenicillin (500 mg/kg/day i.v. in 4 doses) and cephalotin (200 mg/kg/day i.v. in 6 doses), at the onset of fever during granulocytopenia. Patients in the gentamicin group were treated for a total of 541 patient days (minimum 5, maximum 106), and patients in the tobramycin group for 426 patient days (minimum 9, maximum 48). All patients received oral decontamination, which included the amino glycoside (either gentamicin or tobramycin) given intravenously. This study showed that: no patient had an increase in creatinine level above 1.3 mg% and no patient developed renal failure; there was no difference between gentamicin and tobramycin in the efficacy of treating febrile episodes and/or major infections; and prolonged intravenous administration (up to 48 consecutive days in the tobramycin group and 106 consecutive days in the gentamicin group) was well tolerated and effective in treating fever of unknown origin in granulocytopenic patients, i.e., 45 of 72 febrile episodes resolved while the patients had a granulocyte count below 500/mm3.

Original languageEnglish
Pages (from-to)525-532
Number of pages8
JournalTumori
Volume67
Issue number6
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Tobramycin versus gentamicin, in combination with cephalotin and carbenecillin, in patients undergoing bone marrow transplantation'. Together they form a unique fingerprint.

Cite this